<SEC-DOCUMENT>0001104659-15-040051.txt : 20150521
<SEC-HEADER>0001104659-15-040051.hdr.sgml : 20150521
<ACCEPTANCE-DATETIME>20150521172544
ACCESSION NUMBER:		0001104659-15-040051
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20150521
FILED AS OF DATE:		20150521
DATE AS OF CHANGE:		20150521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		15883738

	BUSINESS ADDRESS:	
		STREET 1:		91 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		91 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a15-12546_16k.htm
<DESCRIPTION>6-K
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div>
<div>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">Form&nbsp;6-K</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">PURSUANT TO RULE 13a-16 OR 15d-16</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the Month of May, 2015</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number: 001-37368</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS&nbsp;PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Translation of registrant&#146;s name into English)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">91 Park Drive, Milton Park<br> Abingdon, Oxfordshire OX14 4RY<br> United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;20-F</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;40-F&nbsp;&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.74%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No&nbsp;&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.56%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Yes</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.38%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="47%" valign="bottom" style="padding:0in 0in 0in 0in;width:47.78%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No&nbsp;&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108224\15-12546-1\task7423160\12546-1-ba.htm',USER='108224',CD='May 21 22:18 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Other Events</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;20, 2015, Adaptimmune Therapeutics plc (the &#147;Company&#148;) issued a press release announcing that it has augmented its senior management team with the additions of Lini Pandite, M.D. as Senior Vice President, Clinical Development, and Anne-Marie (Annie) Martin, Ph.D. as Vice President,&nbsp;Head of Biomarker Research and Development. The press release is attached as Exhibit&nbsp;99.1 and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;21, 2015, the Company issued a press release announcing that it will present data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting. The press release is attached as Exhibit&nbsp;99.2 and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibits</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Press release dated </font><font size="2" style="font-size:10.0pt;">May&nbsp;20, 2015</font></p>    </td>   </tr>
<tr>
<td width="100%" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Press release dated </font><font size="2" style="font-size:10.0pt;">May&nbsp;21, 2015</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_122047_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\108224\15-12546-1\task7423160\12546-1-ba.htm',USER='108224',CD='May 21 22:18 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Therapeutics plc</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret   Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate   Secretary</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;21, 2015</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_122136_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\108224\15-12546-1\task7423160\12546-1-ba.htm',USER='108224',CD='May 21 22:18 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a15-12546_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="3" face="Times New Roman"><img width="300" height="66" src="g125461mmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces New Additions to Senior Clinical Management</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OXFORD, UK and PHILADELPHIA, Pa., May&nbsp;20, 2015 &#151; Adaptimmune (NASDAQ: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it has augmented its senior management team with the additions of Lini Pandite, M.D. as Senior Vice President, Clinical Development, and Anne-Marie (Annie) Martin, Ph.D. as Vice President,&nbsp;Head of Biomarker Research and Development.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Pandite will be responsible for global clinical development activities across Adaptimmune TCR programs. Dr.&nbsp;Martin will be accountable for clinical biomarker testing and companion diagnostic development activities.&#160; Drs.&nbsp;Pandite and Martin will report to </font><font size="2" style="font-size:10.0pt;">Dr.&nbsp;Rafael Amado, Adaptimmune&#146;s Chief Medical Officer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;I am extremely pleased to welcome Lini and Annie to our company,&#148; said James Noble, Chief Executive Officer of Adaptimmune. &#147;As a biopharmaceutical company on the leading edge of developing immunotherapeutics for cancer, nothing is more essential to us than continuously infusing our excellent clinical development team with the best scientific minds.&#160; I expect that both Lili and Annie will immediately contribute to the maturation of our organization and our internal clinical pipeline.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Pandite brings over 20 years of academic, medical and pharmaceutical experience to Adaptimmune. She spent 14 years with GlaxoSmithKline (GSK) culminating in her tenure as Head Unit Physician, Oncology R&amp;D, Vice President. While there, she was instrumental in leading the development of several compounds, including Votrient</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(pazopanib), from the first study in humans through marketing authorization and commercialization of its approved indications.&nbsp; She brings strong experience in oncology drug development spanning early to late phase, including clinical trial design, regulatory interactions, and clinical risk management. &nbsp;Dr.&nbsp;Pandite has practiced medicine in both the U.K. and U.S. and is board certified in hematology and oncology.&nbsp; Prior to joining GSK she was an attending physician at Dana-Farber Cancer Institute in Boston, and at Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital in Miami and held academic appointments at Harvard University, and the University of Miami.&nbsp; She received her medical degree from The University of Liverpool, England.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dr.&nbsp;Martin brings nearly 15 years of clinical development and biomarker experience with Pennsylvania Hospital/UPHS and GSK Oncology to Adaptimmune. She began her pharmaceutical career at GSK in 2005, and then held positions of increasing seniority with GSK Oncology, culminating in her tenure as Head of Precision Medicine and Diagnostics, GSK Oncology R&amp;D and Head of GSK Oncology&#146;s Molecular Medicine Unit. During her tenure, she had responsibility for clinical translational research and companion diagnostic (cDx) development for late clinical phase development. She led a global team responsible for the precision medicine strategy in Oncology to deliver all translational research into pipeline opportunities, accounting for over 10 clinical assets and an additional five assets in first-in-human testing, and led the development of the cDx that supported the approvals of Tafinlar</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">&#160;(dabrafenib) and Mekinist&#153; (trametinib).&nbsp; During her tenure, Dr.&nbsp;Martin contributed to three NDAs and</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kgiri\15-12546-1\task7423214\12546-1-mm.htm',USER='105348',CD='May 21 22:52 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">five sNDAs.&nbsp; Dr.&nbsp;Martin has a Ph.D. in Immunogenetics from MCP-Hahnemann University, Philadelphia, PA, and was a postdoctoral Fellow and adjunct assistant professor at the University of Pennsylvania.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform.&#160; Established in 2008, the company aims to utilize the body&#146;s own machinery &#151; the T cell &#151; to target and destroy cancer cells by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune&#146;s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June&nbsp;2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The Company currently has over 100 employees.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains &#147;forward-looking statements,&#148; as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as &#147;believe,&#148; &#147;may&#148;, &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and other words of similar meaning. </font><font size="2" style="font-size:10.0pt;">&#160;These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Prospectus filed with the Securities and Exchange Commission on May&nbsp;7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.&#160; We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune Contacts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kgiri\15-12546-1\task7423214\12546-1-mm.htm',USER='105348',CD='May 21 22:52 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(215) 966-6264</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of PR</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mob: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\kgiri\15-12546-1\task7423214\12546-1-mm.htm',USER='105348',CD='May 21 22:52 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a15-12546_1ex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="301" height="66" src="g125461moi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">OXFORD, UK and PHILADELPHIA, Pa., May&nbsp;21, 2015 &#151; Adaptimmune Therapeutics plc (Nasdaq: ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that it will present data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting. These data pertain to clinical results from myeloma, synovial sarcoma and ovarian cancer patients who have been dosed with affinity-enhanced, TCR engineered T-cells targeting NY-ESO-1. ASCO brings together more than 30,000 physicians from around the world to discuss state-of-the-art advances and persisting challenges in the field of oncology. The meeting will take place at the McCormick Place exhibition center in Chicago,&nbsp;Illinois on May&nbsp;29 through June&nbsp;2, 2015.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Saturday May&nbsp;30, 2015</font></b></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Poster Presentation</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Session title: Developmental Therapeutics and Translational Research</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Abstract number: TPS3102</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Presenter: Melinda S. Merchant, M.D., Ph.D., Clinical Director, Pediatric Oncology Branch, Center for Cancer Research of the National Cancer Institute</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title: &#147;Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Presentation Time: 8:00am-11:30am</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Location: S Hall A</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune&#146;s NY-ESO TCR therapeutic candidate is a novel cancer immunotherapy that has been engineered to target and destroy cancer cells by strengthening a patient&#146;s natural T-cell response. T-cells are a type of white blood cell that play a central role in a person&#146;s immune response. Adaptimmune&#146;s goal is to harness the power of the T-cell and, through its NY-ESO TCR therapeutic candidate, significantly impact cancer treatment and clinical outcomes of patients with cancers, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer and esophageal cancer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform.&#160; Established in 2008, the company aims to utilize the body&#146;s own machinery &#151; the T-cell &#151; to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune&#146;s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June&nbsp;2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108646\15-12546-1\task7423386\12546-1-mo.htm',USER='108646',CD='May 22 00:13 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. The company currently has over 100 employees.&#160; For more information: http://www.adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This press release contains &#147;forward-looking statements,&#148; as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as &#147;believe,&#148; &#147;may&#148;, &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and other words of similar meaning. </font><font size="2" style="font-size:10.0pt;">&#160;These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our final Prospectus filed with the Securities and Exchange Commission on May&nbsp;7, 2015. We urge you to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.&#160; We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune Contacts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President,&nbsp;Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T:&#160; (215) 966-6264</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Head of PR</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mob: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\108646\15-12546-1\task7423386\12546-1-mo.htm',USER='108646',CD='May 22 00:13 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g125461moi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g125461moi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!"`2T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBJ.H:Q
MI^F211WMTD#S'";N]-)O1`7<C.,\TM>;>)=-U_3K[^W8-1>[B'*S1G_5KZ8'
M&VNE\)^*H]>@,$^V.]B&74<!Q_>'^%;2HM0YXNZ(4M;,Z2D)P,FFR2)#&TDC
M!$0$LQ.`!7E7B+Q9J7BG4/[)T191;,VU5CX:;W)[+7-*2B=N&PL\1*RT2W?8
M]7SFEKD-%8^#-)6/Q%KD9WX\N%N?+]@>I'Z5UD<B2QK)&P9'`*L.A%-.YE5I
M<CT=UT?1CZ***9D%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`UF"*68X51DGT%<1J6G:+XVN)+C3]49
M;Y5VB.3[I`_V3SCW%=K/"MQ;R0.2%D4J<'!P1BO/M1\!ZEI^I17.@,75/F4O
M(%:-AVSW%=-#E3?O69$[]BGH&LWGAG56T?55)M&;RY(WY"9_B'M4>O64GA'Q
M/#>V/$#GS8O3'\2_3^AKH?%_AF_UR&RNK>W3[8J;9UW@=O7OSFG:YX=U35?"
M>G6[1*^HVQ`<%P!C&#ST["NE5874N^C,^5[%#XB^(P=$M+.T?`OT$KD'GR_3
M\3_*J^FB#P+X0&JR1*^JZ@`(E;^$'D#Z`<FJ<O@CQ'?7UC]IM8Q!;JD3'SE.
M%#9)Q^-:_CGPSKFOZM;_`&*"-K2&(*K&0#!)YX_`5Y%1-3DU\CZ.C*C[*G1<
MDD]9:_A_78YS1/#5]XLEEUC5KQH;0$E[B0\MCJ%SP`*]!\+ZEHC0'1](O'N1
M9IU?)R,]CW_"LCQ;X?UFZTFQT;1($^Q0H/-'F!-Q'0<]>YJ]X2\%P^'@EW)-
M(]Z\>V7#?(,\X`_K2BFG9(C$UJ=:BY2E_ABNGJ=36#XMUJ72-+46A_TRY<1P
M#&3GN<=__KUO5QUL?^$C\=27/WK/21LCYX:3U_SZ"NNE%-\SV1XDGT1I>$-:
MGU;39([X_P"FVLACF!7!]CC]/PK?KC+[_BF_',-\/EL]4'ER^@?U_/'ZUO\`
MB'6H]!TF2\90[_=C0G[S'I53A>2<>HD[+7H:E<UX[O+FRT*.6TN)()#<HI:-
ML''/%4;/PYK6LPK?:MK5Q`\HW)#!P$!Z?_JK)\6#6--T^+3-1G^W6\DRO!=$
M88$9RK?G6E*E'VB5[BE)VV/1HB3$A)R2HI]8^K6&J7]K;1Z=J7V$`?O6"Y)&
M.,5D3^%-:MHFGL?$=T]PHSMD^ZY]*QC"+WE8IM]CKZ*XB7Q)>7_@.YO%D:WO
MK=Q%(\?'((Y'X4[3;;7/%-A#//J,MC8A`JK'_K)L=6)]S5>Q:5Y.W07-V.UK
M%\3ZW-H=A#<01)(TDRQD/G&#6!?1ZWX,:.]2_DU'3=X66.7[R`_YZU#XY@GN
MK6VU2+4I&L[AXQ';8^521][KUJZ=)<ZN[IB<M&=\#D`^M9NE_P!L_;+[^TC#
M]G\S_1?+Z[??].M4-+T#5[.^BN+GQ'<7<2_>A=,!N/K618ZIJ#IXI+WDS?9B
M?(RW^K^]T]*A4[I\K3V_,=^YW-%<+H=IK?B?289;O59[:T0%1Y9_>3$=6)],
M_P`J@N+W7O!^HK8"X;4HKM,6QEZA\X'_`.KO3]AJXIZAS];'H-%<A)X1UBXA
M^TS>(KG[?]X;>(U/I3_#^MWU[H.IPWK8O=/5T:0<$G:<'ZC%2Z2M>+N/F[HZ
MRBN"\/PZ[XHTB+[3JD]M:Q$J73F2<YSDGT'`_"H[RZUOP3?)%]J;4;2Z4B$2
MGD/V_F/K5>PU<4]1<^E['H-%<@?">L7L/VF[\07"7K#<%CXC0^F*;H.N:A-I
MFKV%_(3?:=&^)1U(P<'ZY%3[)-7B[CYNYV-%8/@N[N+WPS;SW4SS2L6R[G)/
M-0>.KVZL-#26TN)()#.JEHS@X]*E4W[3D#FTN=+17$>)=6U6SUS2(K"9V::$
M?N=V%D8G`W5:E\(ZM<1FXF\1W/VWJ-O$:^P%7[)))RE:X<W9'6T5R7AGQ'<?
M8]0M]9<&?3,[W[LHS^N1^-5].M=7\8(=0N]1FL;!V/D06YP2!W)I>Q:;YG9(
M.;L=K17%33:GX,U"V^T7TE_I5P_EGS?OQ'ZUV@((!!R#T-3.'+9[IC3N1W,K
M0VLLJ)O:-"P7^\0.E>73ZGK?C35XH[426Z+\N(G8+&.Y8CK7JM<5XLUV_P!`
ME&GZ9816T<XRDZ+RQ[X`[UMAGJTEJ1/8SO'.IFW-EHUE<RE[9!YC)(02V,`$
M^O?\:F\57%QI/A'2M-:YD%TV&D<.0V`.<GKU/Z5#X>\-FT8^(/$3&&.(^8J2
MGYG;U;_"L]FN?'/BP85D@!Q_USB!_F?ZUTQ4;I=(ZM^9#O\`>95_+J&BWVEW
M3W=UMEBCN"&F;!.[D=>G`K=^)#7<&H6.JV=W.+>YB`!CD8)D<CH<<@_I6_X_
M\.?VEH4<UG%F:P&511]Z/'(_3-<_X7U*R\2Z"WA75I-DJC_1)3UXZ`>X].XK
MQJCYIR\]3Z?#S7L:=5*_)I+T[ESQ/'=^)O#EEKNC3SEXH]MQ##(P/OP.I!_2
MK?@+Q9?ZQ)_9=W`'-K%EKC)#$#``(]:Y56\1?#[46`0M`YYR"8IA_0_K7J&A
ML;K3X]0GTZ.RNKE0TBJ!D^F32CK*YEBE&E0Y;*47\+OJB+Q1JW]C:%/<*<3,
M/+B_WCT_+K7-:)IGB_2M/$=E%9*DI\PF0_.2?6N@UGP_+K.KV,\UPGV*T;>8
M"N2[?7TZ5NUW*HH0LM;[G@VN[G!:WI?B_5M/:&]CLFCC/F`QG#`CTJGK&J-J
M_@W3+YU+M9W2K<CW`QS]?ZUZ37-V?A);:_U(/*DFFWXRUL5(*MZ@_G6D*R^T
MK6_IB<7T-^VGCN;:*>$@QR*&4CTKE/B/=0)I-M:L09I+A75?89R?UHA\+Z_I
M!:'1M;5;4GY8YTW;/I27G@66\LBUQJ)N-1>16>YE7("C/RJ.PI4U3A-2YM`=
MVK6#5+C4-6\20>'[:\:SMTMQ+,\?#N/05<_X0JSB7?'J6HQ2+SYGVDG'OSQ4
MFM>%WOKJ#4;"\:SU"!0HD`RK@=B*A&B>(=0'DZMK*"U/WX[6/8T@]"WI1S+E
M7+*W<+:ZHY:TQ_P@6M`.7'VH8<_Q<CFNZ\,7,%UX<LG@P%6((5'\)'!%<UJF
M@-X?\$ZI`9ED668.FT$;1D8%6;'PW>Q6%K?:%J)LI)H5::%QNC=L=<=C6E3E
MG%Z]?T%&Z9I^-KF&W\*W@E(S*`B#U;(__77/Z]$\'@/1XY00PDC)S^)K3M_"
M-Y?7\=YXAU'[;Y1RD"#"`UL:_HD.O:6UE(YB((:-P/NL.G'I6<9QARQO?6[&
MTW=FFOW1]*\]T_\`U?C#ZM_[-70:/I'B&SNH?M^LK<6L((\M4Y?TR:9;>%9H
M%UL&ZC;^TR2F$/R9SU]>M*#C"ZOV_,;NRUX,_P"13L/^N?\`4UF^+?\`D9?#
MO_7S_45O:'ISZ3H]O8/()&A7!91@&JNLZ%)JFJZ9>).L:V,N]E*Y+<CI^5*,
MXJJY=-0:?+8VJX;0O];XM_WY/Y-7<US^G^&Y;)]99KE'_M)F*X4C9G/7UZU-
M.246GY?F.2U0G@3_`)%"R_X'_P"A&L_QW_Q_:'_U\G_V6M[P]I3Z+HL&GR2K
M*T6<NHP#DD_UJOXAT"76KBPDCN$B%I+YA#*3NZ<?I51G'VSETU$T^6QMUPE@
M"?$?BT`<F`X_(UW=8>F:!)8Z_J>I23I)'?8Q&%Y7'KZU-.2BI7_K4<E>Q6\`
M2(_A2!58$H[*P]#G/]:J_$>9$T."(GYY+A=H^G6D/A#4],OI9_#^J"VAF.6A
MD7(%-OO!%YJ5J9+[5?/OBPQ(Z_)&HZA0/7UK9.G[7VG-H3KRVL1ZN`?&GAW(
MS^Z']:[:L&]\/2W6NZ9J(N$5;%`K(5.6^AK>K&I)-1MV*BK7/-KB&2?4/&$<
M2%F,:G`]`V3^@J_X>TC4]1T.VN+/Q+/#%MVB)8QB,CM6]IGA^2QU_4]2DG22
M.^P!'MY7Z^M4)/"=_IMY)<>'=2^R)*=SV\J[DS[5NZL6N5/M^1'*]R*]\':E
M?0>1>^)9I8F8':\8QGMWKK88_*@CCSG8H7/K@5S,'A?4KV]BNM>U4W"PL'C@
MA&Q`P[FNIK"K*]E>Y<4%-:-'*LR*2IRI(S@^U.HK$H\\U[P_XJUG6!!<2));
M9S'(IVQH/<=<UUV@:!:Z!9>1!\\C<RRD<N?\/:M6BMIUI2BH[(E12=Q*\\\7
M?#Z22=M2T)0')W/;`[>?5#V^E>B45SRBI*S.K#XBIAY\T&<[X4M-<&E>7XB>
M.7./+C=0SJ!_>/0FNBHHII61G4J.I)RM:_8HC6=/.H_V<+D?:O\`GEM.?Y8H
MGUG3K:^6RFNDCN'QA#GOTYZ<TX6`&KG4=_)@$.S'^T3G/XU0O_#4=]JPU%KE
MU<-$1'C*'82<$9YSG\,4M2XJBWJW:WX_<:=W?6MA&DEU,L*NXC4MW8\`4ZZN
M[>RB$MS*L2%@FYNF2<`?G69KWAV/Q!Y27%W-%%$"52+`^<]&)]O2I[[1UU+2
MX;"[E\U49#(Q7_6;3SD=LT:B4:5HW?J6UO+=H9)A,OEQ%E=R<!2O!S],4VSU
M"TU"V-Q:S"2($@M@CI]:J:?HB:?H\FFK.TJ.9"'D`8@,2<'/7&<4:/HW]DV,
MEK]I,H=B1\NT)D8P!DX'XT]0<:=G9]=/0L6&JV.IJS64XF"=2%(_F*2#6-/N
M;U[*&[C>=,Y0>W7!Z''?%,T?1K?1K);>#<QP`[DGYB.^">/PJI8^'!9W<#F\
M:2WM&D:WAV`;"_7+=6ZFEJ-JC>5F[="75KG1KUFT;4)UW2[<Q$D=>G/3G%6#
M=:?I20V;SI"%B)C5S_`HY/X"J5YX:CO-7.HFY=7WQ-Y?5#LSP1GGK^&*DU?P
M[::U=PS7GS+#&RA,=R0<Y_#I[T^:5K#4:%U=O;7U+PU"T-BEZ)U^SN%*R=CD
MX'\Z=/>VUK+#%/,D;SDB-6/WB!DX_"J1T53H,6E>>=L80>9MY.U@>GX4FM:#
M!K9A^T2,HA#[=O4%A@,#V(Q2U)4:7-J]-?\`@%UK^T2Q^W-.BVVP/YI.!@]Z
M6SO;>_MUN+63S(F)`;!'3V-49="270(=*:=OW"H$EP,[DP0<?4=*ETC3&TNW
MEC>X:=Y93*S$8`)QP!DX''K3UN#5/E;3UO\`@7R0JECT`R:IV&KV&J&065P)
MO*.'PI&/S%7:J:?8"P%SB0OY\[S=,8W=J-2%R\KOOT$OM6L--:-;RY6)I/N@
M@DGWX[>].O=1M-/1&NIA&)&VIP26/7@"JU]I4MQJ$=]:WGV:98C"V8@X9"<]
M#T/O3-=T/^VH[=?/$1@DWC<FX-QCG!'KZTM32,:5XW?K_5O\S0>[@CACE>0*
MDK*J$@\EN@I;BYAM8Q)/($0L%!/J3@#\S52_TV2\T^&W6X$4L+QR+)Y>1E3G
M[N>GXTE_IL^H:6MK)=*LZNC^<(N"RL&^[GIQZT]25&&EWU_`T:IZAJMCI2(]
M]<"%9#M4D$Y/IQ5B!94@19Y%EE`^9U7:"?IDXJMJFG+J=O'"TAC\N:.7(&<[
M6!Q^.*'>VA,%'FM+8F:\MU2%FE`%P0L6?XB1D4P:E9FP:^$Z_9E!)DYP,'!J
M+5=)AU9((YV(CAF$A4?Q8!XR.G6JT?A](_#3Z(LYV,C()-O(R2>GXTM2TJ5E
M=ZW_``+\%_;7-JUS%)F)<Y8J1C'7J*;8:I8ZFC/97"S!<;L9!&>G!J"QTDVF
MD2:>TRL'5E#(A7&1Z$G^=1Z+H,>BF;RYWF$H09DY9=JXQDGIWQVHU&XTK2L]
M>A?BO+:>YFMHID>:`@2H#RF1D9J$ZOIXU'^SC=(+K_GF<YZ9QZ=*H:;X;&FZ
MH^HK?32S3;_/5P-K[CD8';'XU,GA^U_MJ;592TLKNKQJ20L9"[<XS@GW-&HW
M&BF]6U;\2W/JEC;3-#-<*DB[<J<Y^8X7'KDU;JA=Z3#=ZK9:@^-]INP"N=V1
MZ^W6K]-7,I<MER_,****9`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!__
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g125461mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g125461mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!"`2P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBJ.H:Q
MI^F2117MW'`\Y(3=WII-Z("[D9QGFEKS7Q+INOZ;??VY#J+W<759XS_JU]"!
MQM_2NH\)^*8]?MS#-MCO8AEU'1Q_>'^%;2HM0YT[HA2ULSHJ0D`9/`ILLL<$
M3RRN$C0%F8G``%>4^(/%6I^+-1_LK15E%LS;51.&E]V/85RRDHG;AL+/$2=M
M$MWV/6*6N2T:7_A#=*2#Q%KL;L^/+B;DQ^P/4C]*ZM'61%=&#*PR".A%4G<R
MJTN1Z:KH^XZBBBF9!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`-9E1"['"J,DGL*XC4M.T7QM<27&G:
MHRWRKM$<GW2!_LGG'TKM;B%;BWD@<D+(I5L'!P1BO/M1\":EIVIQ7.@,75/F
M4O(%9&';W%=-#E3?O69$[]BGX?UJ[\-ZJVC:JI-HS>7)&_(CSW'L:CUNSD\'
M^*8KRRR(&/FQ>FW^)*Z'Q?X9O]<CLKJVMT^UJFR==X'Z]^<T[7O#VJ:MX7TV
M$Q*^HVV`X+@#&,'GIV%=*J0NI=]&1RNUC/\`B/XB!TBTL;1\"^032$'G9V'X
MG^50V7D^`_""Z@T:OJVH`>6&_A!&0/H!R?>J;^"/$5[J=@UW:QK;P+'$Q\Y3
MA%/)Q6KXX\,:YX@UN!K2",V<,856,@&"3\W'Y5X\TU.37R/HZ,J/LJ=)R23U
MEK^']=CGM#\,7GBEI=9UB]:&SR2]Q(?F?'7&>`*]"\,:GHLUM_96D7CW"V2@
M9?))&?4]:QO&/A_6K[3[+2-%@3[!!&/,'F!-Q'`!]?7ZUH>$_!L'AQ1<M-))
M>21[9?F^3UP!1%-.R1GBJU.M1YI2_P`,5T]3IZY_Q=K4^E6$45B?].NI`D(P
M"?<X[^GXUT%<=IW_`!4?C:XU$_-::8/*AYX+^O\`,_E7722OS/9'B2?0U/"6
MLRZQI)-T?],MW,<XQCD=\5NUQDF/#?CQ9/NV>K##>BR?_K_G6YXEUQ=!TEKD
M*'F8[(4/=C_054X7FN7J">FIKUS'CB]NK*RL6M;B2!GNT5C&V,CG@U4M?#&L
MZG$MYJVN7,,[C<L4/`C]O_K5C^)SJ]D++3-3E%W']I62"[Q@L!P58>O-:4J<
M>=6=R92=MCTD=!2UD:UIVJZAY":?JAL(P#YI5<L?3'ZUBW7AC6[&![G3O$-U
M+-&-WER]'QVK&,(M:RL4V^QV-%</J'B6[OO`2ZE!*UM=+,(Y&C..0><>QJ>T
ML-:\46L5W=ZE+86;*/*AA^^XQ]YC[]:KV+2O)VZ"YNQV-8GB/6YM&:P$,22?
M:K@1-OSP/45@W,FL^"KF&::^?4-*D?8_F?>CS4'C6RNGOK&[75)&@N[A1!%C
MB$X'S#FKIT5SJ[NF)RT._/2LW1?[9VW/]L&'/G'R/+_N=LU3TG0M5L+X3W?B
M">]B"D>2Z8!/KUKGK'5]2D\*Z_</?3&:"?;%(6Y09'`J(T[IJ+3V&WW/0**X
MG3--UKQ-ID-U?:M/:6Y0"*.'[SX_C8^YJF=0\1>'=3;0A/\`;GN5`M)9/X<]
M_P`.>*?L+MI2U0<WD>A45QUQX1U@0&ZB\174E^HW<G",?0>E+:>(+S4/`=_=
MO(8KVU5XVD3@[ACGVZU/LKJ\7<?-W.PHKB-(L=:\3Z5!/>:K/:6P3:BQ??E(
M_C8^YJK)?^(/"VI?V/\`:/[0^UJ!:/+U5B<9_#TJO87;BGJ+GZV/0:*X^;PC
MK#PFY'B*Y-^!NZX3/H/2H;7Q%>WW@C4I))6CO[(%&D3@Y['Z]:7LKZQ=Q\W<
M[:BLSPY/+<^'K&:>1I)7A!9V.2363XSO[NRGTD6MS)");G:X0XW#C@U$:;<^
M0;>ESJ:*XC6=2UI/'`T_39V_>P@+&Y^1"1RQ'L.:GNO".KK";J#Q%=/?*"WS
M'"L?0<\5?LDK<TK7)YNR.PHKD]'\7%O"MQJ&H`&XLR8W4<;V_A_$U#I^BZOX
MCMEU'5M6N+99ANBM[8[0@/0TO8M7YG:P^;L=E17'6E]J?AK7H-*U.[-[9WG$
M$[_>0^AKL:B<.4:=R*ZE:"UEF1-[1H6"Y^\0,XKR^;4M;\::Q'':B2W1?EQ$
M[!8QW+$=37JE<3XKUV_T"8:?IEA%;1SC*3HO+'O@#O6^'>K26I,_,SO'.IF!
M[+1K*XE+6J#S&1R"6(P`2._^-3>+;BXTGPKI6F&YD^TD!I'#D-P.<GKU/Z5'
MX>\.&R)\0>(F,,<1\Q$E/S,W]X^_H*SA]I\<^+`=K)`"/^V<0/\`,_UKIBHW
M2Z1W?F9N_P!YF7LM_H>J:7<R7=ULDCBN"'F;!YY'7I6U\1VN[35[/5+.[G%O
M<Q`KLD8)N7D=#CD&M[XA>'/[1T..YM(\S6`X11]Z/N/PZ_G6'X:U"R\4^'SX
M7U64)<1C-I,>IQTQ[CT[BO&J.\Y>>I]/AYQ]C3K)7Y=)>G<M>+(KOQ%H5EX@
MT:XG.R/;/##(P(]>!W!S^%7O`?BR_P!<9M/NX%+6L0+7&<%NP!'K7)13>(_A
M]J+(8R8';D$$Q3#U![']:]2T7,UA'?2Z?'97-RH:5%`S[9/>B&LKF6*4:5#D
MLI1?PN^J*OBW5CI&@S21G]_-^ZA`Z[C7/:-IGC#2=/6WLXK)8V.\^8<L2?6M
M_5?#\NK:[97<]PGV.T^80;<EF]2?R_*MVNY5%""BM;[G@VN[G`:]IGB[5-/(
MOH[,I;GS5,1^<$#M4&MZL-5\/:'JLB;UM[D"Y'HPQU^N/UKT7K7-6/A!+:74
MK>:5)M-OCN$&T@QGU!JX5HV]Y6M_3$XOH='%*DT22QL&1P"I'0BN/^(5U"$T
MVTW`S&Y60#T4<9_6GP>&?$6E`V^E:XHM3]U9TR4'M1<^!I+F"*234#-?^>LD
MMS,I.5'\('84J:IPFI.6@.[5K!J4E_KOBN30X;U[.TMH1)*8CAY,X[_B*LR^
M#;.WA:6+4]1@9%),GVDG''<'BI=9\,2W>I)JVF7ILK]5"LV,JX]Q47]@Z[J:
M^5K6KH;;^*&UCV>9[$^E'.K+EE9!;NCE$Q_PK2?!W#[=U]:]$T6YAN]%LYK<
MCRS"H`';`QC\*X[7-$?0/`DMH\RRDW8<%5P`">E:,/AK4;2&*YT#4_LBS1JT
MEO(NZ,L1R1Z5=3EG&]^K%&Z9/\0+B*+PQ)$^"\SJL:]R<YK-\21/!I?AJ*3A
MTGC#9]<"K]CX1N)M134=?OS?31',<0&$4UI^)-`3Q!8+`9C#-$^^*0<[6]ZF
M,X0<8W&TW=FL>E>:6'_(F^)O^OD_S%=;HVF:_:W0?4]76YA1"HC5,9/J35.V
M\'SP:'JNGF\C+7\N]7"'"<]^>:5-QA=-]OS!W9L^'?\`D7;#_K@O\JPM;_Y*
M'HG_`%S?^M=+IEHUAIEO:,X=H8PA8#`.*S[_`$*2\\2V&K+.JI:*08RO+9SW
M_&HA)*;;\RFM$;5>=:/_`,B1XB_ZZR?R%>BUS%EX4GM=`U/36NXV>^=F5PAP
MN?444I**=^Z%)-FCX6_Y%?3O^N"UB>)/^1ZT'_/>NETBQ;3=)M;)W$C01A"P
M&`<50U30)=0\0:=J:W"(EG]Y"I);GL:(R2J-^H-.QMUYO8*6T#Q:%&3YQ_F:
M](K!T3PV=,_M-;F5+B._E+[0I&`<\'\Z*4U%._E^8Y*[)O"4B2^%M/*,&`B"
MG'J.#6)X\F3[?HL&?WGVC?CVR!2P^$];TB5TT365CM7;/E3+G;3I_`]Q<2VU
MU/J9GO4F$DTTJGD#HJCL*TC[.-3GYB7=JUA&`/Q47CI:_P#LM=A6*=!E/BX:
MYYZ>6(?+\K:<],9S6W6-22?+;L5%6N>4-"\GAG73&I(CU)7;'9>>?UKI]/T3
M5[S3X+FW\57/E21AE`C'`QT_"M+0O#?]F1:C%=21W,=]*7*A<``]C6>GA;6=
M(D==!U<1VSDD07"[@GTKIE54KI,A1:";P??W5Q;/?>(9;CR)!(B/&.HZXYKK
MJYO3?#-Y_:4>IZSJ;WEQ%_JD3Y43\.]=)7-5E>RO<N*"FM&CE69%+*<J2,X/
MM3J*R*//-=\/>*=:UD07$B26V<QR*=L:#W'7-=?H.@VN@6/D6XW.W,DI'+G_
M``]JU**VG6E**CT)44G<0C(KSKQ9\/IC<-J6@J`Q.][93M(/JA_I7HU%<\HJ
M2LSJP^(J8>7-`Y_PM:ZV-)">(GBF;CRT9064#^\>A-=!1132LC.I-SDY6M?L
M44UC3Y-1.G+<@W2YS'M.1^F*676-.AU!;"2Z1+EB`(SGJ>G/3FG+8!=7DU#?
MR\"P[,=,,3G/XUGW7AJ.ZUD:F;EPXDC?R\90[`>",\]<Y[8I:EQ5%O5NUOQ^
MXU+J]MK(1&YF6+S9!&FX_>8]!2W-W;V:HUS*L2R.(U+'@L>@K+UWPW'K\D1G
MO)HDA4^6L6!AS_$3WQCI5G4M'CU:Q@M+Q_,6-U>3Y?\`68'/TSFC42C2M&[]
M2U]MMOLCW7G*($W;I"<`;20?R(--MM0M;NS-W!,'@&27P1C'7@\U4M=$6UT`
MZ1Y[2J5=?,D4,3N8GD=^M&G:-]@TB73S<M*)-_S;<!`PQ@#)X'UHU!QI6=GU
M_`LV&IV>IQM)9SB5%."0I'\Q3;76-/OKF2VMKM)98\[E'L<''KSZ4W2](MM*
MT\6<()7:`Y+$[CC&>3Q^%5-,\._V?<P.UXTT5HCQVT?EA=@8\Y/\1XQ1J.U'
MWK-^0[5)=$U24Z+?3JTA=<Q9(.[J!GIGVJW+J&GZ;BVFN8X3%"9-KGI&O&:H
MR>&HY-:_M0W+[_/67RS]SA=N",XSW![4NK^&;/6KT7-V=VV`QHN/NG.<^_T]
MJ=Y6L-1H<RNW:VOJ:;7MLD$4[3*(IBHC;^\6Z?G3;C4+2TE6*XN$C=T9U5CR
M57EB/I5>721+IUI9^<0+5HV#;?O;/\:@USPY!KK*TTKQE(7C1D'*%B/F!]L?
MCFD[DQC2<ES/37_@%^>_M+:S^V33JD!`(<]\],>M/MKF&\MTN+=]\4@RK8(S
M^=4[W1UN]-MK43F-[5D>.3;G#+T)'<>U2:1IO]E6`MO/:8[V<LWJ3G`&3@?C
M3UN)JGR73UO^!;DD2*)I'.$0%F/H!5>PU2RU2-I+*<3(AVL0",'\:MU3TRP&
MFV?V=9#)^\=]Q&/O,6_K1K<E<O*[[A=:M865U%;7%RJ32XV)R3R<#..G/K2W
MFIV=@\:74WEM+G8NTDMCKT'O5>?296U4W]M>&`R(J3(8@^\*21@GIU-1ZUH7
M]K7-I.)UC:VW8#1E@V<>A'I2U-(QI75WIU_JW^9I27,,31*\@4S-MC!_B."<
M?D#1-<0VYC$L@0RN(TS_`!,03C]#534M/FO5MF@N5@FMI?,5S'O!.TCID>M)
MJ6G3W\%J$NEAGMIEE$ABW`L`1]W/OZT]25&#M=FC5*^UC3]-ECBO+D1/+]P%
M2=WY"K<8=8U$C!G`&Y@,`GUQ5._TU;^XLIC(4^R3^:!C.[@C'ZT._0F'+S>]
ML3S7EO`R++*J,ZLR@]P!D_I3)=3LX;!;YYU%LX4K)@D'/2JNL:%!K+PFX8A8
M5<!1GDL,9R#VJ.ZT!;GP[#I'VC`B$8$A3.=I!Y&>^/6EJ:1C2M&[]2^=0M%L
M&OFEVVZKN+LI&!].M+9WUKJ$)FM)EE0':2.Q]"#TJH^C^;X?;27F`#1[-Z(1
M@9[`D_SI=,TC^RK6Y@@N&<S2-(LD@W,">F3GYL4]1-4^5V>M_P`"W;7EM>>9
M]GF67RG,;[3]UAU%0P:OI]U>R64-TCW$9(:/D$8Z_7%4M#\.)H4LC0WDTRS(
M!(LN#EP?O#'3J>*ET_P_:V%_/?$M+<2RNZLQ.(PV,@#..W6EJ-QHIRLV^Q:_
MM2Q%S]F^T+YWF>5Y?.=V,XQ].<U;JA_9,/\`;O\`:W'F^1Y.-OOG.?7M5^FK
MF<^73E"BBBF0%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
G%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
